A pharmacoepidemiological study of prescription patterns of \( \beta_2 \) sympathomimetic bronchodilators in exacerbation of non-severe asthma in tertiary care hospitals, not needing hospitalization

Moumita Hazra*

ABSTRACT

**Background:** Arformoterol, the (R, R) enantiomer of the racemic (R, R/S, S) diastereomer, formoterol, is a short and long acting \( \beta_2 \) agonist bronchodilator. Levosalbutamol, the (R, R) enantiomer of racemic diastereomer (R, R/S, S) salbutamol, has a greater affinity for the \( \beta_2 \) receptor. Occupation of \( \beta_2 \) receptors by agonists result in the activation of the Gs adenylcyclase-cAMP-PKA pathway, followed by phosphorylative events leading to bronchial smooth muscle relaxation. The aim of this pharmacoepidemiological study was to analyse the prescription patterns, and prescription content analysis, of arformoterol, levosalbutamol, formoterol or salbutamol, in non-severe asthma exacerbation in tertiary care hospitals, not needing hospitalization.

**Methods:** It was a multi-centre, retrospective, observational and analytical study of 100 asthmatic patients’ hospital medical records, treated with 3 doses of arformoterol, levosalbutamol, formoterol or salbutamol nebulization, followed by peak expiratory flow rates (PEFR) measurement at the baseline and 6 minutes, after each dose; along with adverse effects recording. The number of prescriptions of 100 patients was recorded, the percentage of prescriptions was calculated, and the prescription content analysis was done.

**Results:** PEFR of the patients showed significant increase after the first, second and third doses of bronchodilator nebulisation, with negligible adverse effects. Salbutamol was most commonly prescribed (45 prescriptions, 45%), followed by levosalbutamol (35 prescriptions, 35%), formoterol (15 prescriptions, 15%) and arformoterol (5 prescriptions, 5%). All aspects of prescription content analysis showed 100% completeness.

**Conclusions:** Arformoterol was more effective, but equally safe, as compared to levosalbutamol, formoterol and salbutamol. Prescription frequency of salbutamol was followed by levosalbutamol, formoterol and arformoterol. Prescription content analyses showed 100% completeness.

**Keywords:** Prescription patterns, Arformoterol, Levosalbutamol, Salbutamol, Formoterol, Non-severe asthma

INTRODUCTION

Asthma is a global health problem affecting around 300 million individuals of all ages, ethnic groups and countries. Asthma is a chronic inflammatory disease of the airways, characterized by increased bronchial hyperresponsiveness, bronchoconstriction, microvascular leakage and plasma exudation, due to activation of M_{1} receptors on bronchial smooth muscle by increased cGMP levels, on release of acetylcholine, caused by released histamine, leukotriene C_{4}, D_{3}, B_{4}, prostaglandin D_{2}, protease enzymes, TNFα, platelet activating factor, interleukins (IL-4, IL-5, IL-13), adenosine, eosinophil cationic protein, neuropeptides (substance-P and neurokinin-A), from the allergen induced activated mast cells, infiltrating eosinophils, basophils and T helper 2 lymphocytes. The symptoms of asthma are breathlessness, wheezing, cough, and chest tightness at night and in early morning. Non-severe asthma, if mild, is defined as the degree of asthmatic severity, wherein patients are dysnoeic only with activity, with a peak expiratory flow (PEF) ≥ 70% of predicted or personal best and SpO\(_{2}\) > 90%; and, if moderate, is defined as the degree of asthmatic severity, wherein patients are
dyspnoeic, which interferes or limits their usual activity, with a PEF 40-69% of predicted or personal best and SpO₂ >90% [unlike, severe asthma, which is defined as the “uncontrolled asthma which can result in frequent severe exacerbations (or death) and/or adverse reactions to medications and/or chronic morbidity (including impaired lung function or reduced lung growth in children”).]

The different β₂ sympatomimetic bronchodilators are short-acting β₂ agonists like salbutamol, levosalbutamol, metaproterenol, terbutaline, rimiterol, fenoterol, tulobuterol, and pirbuterol; long-acting β₂ agonists like salmeterol, formoterol, and arformoterol; and ultra-long-acting β₂ agonists like indacaterol, carmoterol, milveterol, GSK-642444, BI-1744-CL, LAS-100977, and PF-00610355.

Occupation of β₂ receptors by agonists result in the activation of the Gₛ-adenylly cyclase-cAMP-PKA pathway, resulting in phosphorylative events leading to bronchial smooth muscle relaxation, by the following molecular mechanisms:

- Lowering of [Ca²⁺]₀ concentration by active removal of Ca²⁺ from the cytosol into intracellular stores and out of the cell.
- Acute inhibition of the PLC-IP₃ pathway and its mobilization of cellular Ca²⁺.
- Inhibition of myosin light chain kinase activation.
- Activation of myosin light chain phosphatase.
- Opening of a large conductance Ca²⁺-activated K⁺ channel (KCa), which repolarizes the smooth muscle cell and may stimulate the sequestration of Ca²⁺ into intracellular stores. β₂ receptors may also couple to KCa via Gₛ (stimulatory G protein) so that relaxation of airway smooth muscle may occur independently of an increase in cAMP.
- Increased Na⁺/Ca²⁺ exchange.
- Increased Na⁺, Ca²⁺ - ATPase activity.

The β₂ sympathomimetic bronchodilators inhibit the release of bronchoconstrictor mediators from inflammatory cells and of bronchoconstrictor neurotransmitters from airway nerves, by the following mechanisms:

- Prevention of mediator release from isolated human lung mast cells (via β₂ receptors).
- Prevention of microvascular leakage and thus the development of bronchial mucosal oedema after exposure to mediators, such as histamine and leukotriene D₄.
- Increase in mucus secretion from submucosal glands and ion transport across airway epithelium; these effects may enhance mucociliary clearance, and thereby reverse the defective clearance found in asthma.
- Reduction in neurotransmission in human airway cholinergic nerves by an action at presynaptic β₂ receptors to inhibit acetylcholine release. This may contribute to their bronchodilator effect by reducing reflex cholinergic bronchoconstriction.

Arformoterol is the (R, R) enantiomer of formoterol, a short and long acting β₂ agonist bronchodilator and is distinguishable from the most commonly used racemic (R, R / S, S) diastereomer of formoterol. In vitro data show significant bronchodilatation, inhibition of inflammation and marked baseline airway reversibility with arformoterol. Salbutamol is the most common β₂ agonist being currently used in the treatment of asthma. It is a raceme, and a 1:1 mixture of the dextro [(S)-salbutamol] and levo [(R)-salbutamol] rotary forms. Levosalbutamol is the purified enantiomer of racemic salbutamol (both R and S) that has a greater affinity for the β₂ receptor as compared to (S)-salbutamol. Levosalbutamol is a single isomer β₂-agonist that differs from racemic salbutamol by the elimination of (S)-salbutamol. Formoterol is a unique β₂ agonist, being both rapid and long acting. There are few demonstrations of formoterol being more efficacious when compared to salbutamol; and both the therapies being well-tolerated. The enantiomers of β₂-agonists in the R configuration are primarily responsible for the bronchodilating effects of the racemate. The plasma concentrations of the enantiomers of anti-asthma drugs may differ as a reflection of stereoselectivity in clearance, volume of distribution, and route of administration. With β-agonists being the most widely used agents in the treatment of asthma, in vitro studies reported that β-adrenergic receptor (ADRB2) polymorphisms are associated with agonist-promoted down-regulation. Non-synonymous single nucleotide polymorphisms (SNPs) of ADRB2 at codons 16 and 27 are significant.

The aim of this pharmacoepidemiological study was to analyse the prescription patterns of different of β₂ sympathomimetic bronchodilators, like arformoterol, levosalbutamol, formoterol or salbutamol, in the exacerbation of non-severe asthma in tertiary care hospitals, not needing hospitalization; because there is a dearth of relevant study literature.

**METHODS**

**Study type**

It was a multi-centre, retrospective, observational and analytical study of the hospital medical records.

**Study population**

100 patients, who had earlier attended the respiratory Medicine out-patients departments of tertiary care hospitals, and were treated for exacerbation of non-severe asthma, not needing hospitalisation.
Study place

Departments of Pharmacology and Respiratory Medicine of Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India; J. J. M. Medical College, Bapuji Hospital and Chigateri General Hospital, Davangere, Karnataka, India; and departments of Clinical Pharmacology and Respiratory Medicine of Hazra Polyclinic and Diagnostic Centre, Hazra Nursing Home, Domjur, Howrah, Kolkata, West Bengal, India.

Study period

5 months (the research study was conducted within the months of September 2012 to January 2013 and the compilation of the study literature was done within the months of March-April, 2017).

Selection criteria of the patients

The patients were selected based on the inclusion and the exclusion criteria given below, and the patients fulfilling those criteria, were included in the study.

Inclusion criteria

The inclusion criteria were patients’ age >18 years, and of either sex, British Thoracic Society definition of acute non-severe asthma, patients’ ability to perform forced expiratory manoeuvre, and co-operative and conscious patients.14

Exclusion criteria

The exclusion criteria were uncooperative and unconscious patients, patients presenting with acute severe or acute life-threatening or near-fatal asthma, history of hypersensitivity to the study drugs, pregnant or lactating women, other associated medical illness having impact on study results and children or very old patients.

Ethical approval

At first, the clearance and the approval from the Institutional Ethics Committee were obtained. The study was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and Good Clinical Practices contained within the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH-E6), and in compliance with the regulatory requirements. Written permissions to access the relevant hospital medical records were obtained from the hospitals, outlining the aims of the study. The study involved almost negligible risk, of any type, to the patients. The design provided an equal opportunity to all the eligible patients treated for non-severe asthma to be included in the study. The patients who were included in the study were assured confidentiality, and an informed consent was obtained from each individual.

Methodological procedure

After obtaining the clearance from the institutional ethics committee and informed consent, the following data of the thorough patients’ history with complete examination details and prescription patterns were obtained with the study proforma, from the hospital medical records of the patients treated for exacerbation of non-severe asthma, not needing hospitalization: the patients’ participation assessment and adherence to treatment (including patients who completed the study thoroughly, number of drop-out patients to adverse effects, patients who were lost to follow-up and patients who withdrew voluntarily); the demographic characteristics, including age, gender, race, body mass index, duration of symptoms of asthma, severity of asthma symptoms, present controller medications, the patients’ present and past history, smoking history, respiratory history including respiratory immunologial history and history of allergy, chronic obstructive pulmonary disease and asthma, cardiac history, history of co-morbidities, family history, personal history, socio-economic history, reproductive history, concomitant medication history, and surgical history were recorded. The Saint George’s Respiratory Questionnaire (SGRQ) scores, and the Baseline Dyspnea Index (BDI) / Transition Dyspnea Index (TDI) questionnaire scores, were recorded, to assess the effect of treatment on asthma.53 Details of complete general physical examination, and systemic examination, including oto-rhino-laryngo-tracheal, respiratory and cardio-pulmonary examinations, were recorded. Pulse rate and oxygen saturation of arterial haemoglobin (SpO₂) measurements with pulse oximeter, and respiratory rate were recorded. Using a peak flow meter (Breath-O-Meter), the baseline peak expiratory flow rate (PEFR) was measured. Peak expiratory flow rates were measured at the baseline and 6 min, after each dose. The 100 patients were treated with (i) 3 doses of nebulization with 15 μg arformoterol respules (totally 45 μg), through oxygen driven (6 L/min) nebulizer, three times a day, or, (ii) 3 doses of nebulization with 0.63 mg levosalbutamol respules (totally 1.89 gm), with the same nebulizer, three times a day, or, (iii) 3 doses of nebulization with 15 μg formoterol respules (totally 45 μg), with the same nebulizer, three times a day, or, (iv) 3 doses of nebulization with 5 mg salbutamol respules (totally 15 mg), with the same nebulizer, three times a day. Corticosteroid was added to the nebulization, after the third dose of the drug was administered, to eliminate the impact of other drugs on the treatment outcome. 6 minutes after administering each dose of the bronchodilators, PEFR was measured. Best of the three PEFR measurements was recorded, at each recording. After the third dose, patients were followed up for a period of 10 hours, for the occurrence of any adverse effect. To evaluate the significant improvement in either group, one sample test was used to compare the PEFR before and after each dose of the drug. The prescription patterns of all 4 drugs were analysed. The number of prescriptions of 100 patients treated with each drug:
arformoterol, levosalbutamol, formoterol or salbutamol was recorded, and the percentage of prescriptions for each drug was calculated. The prescription content analysis, of all the 100 prescriptions, was done. The different aspects of prescription content analysis were: (i) completeness of prescription contents, (ii) mention of the dose of drug, (iii) mention of the duration of treatment, (iv) mention of the instructions of medication, (v) mention of the frequency of drug intake, (vi) mention of the name of the drug, and, (vii) mention of the dosage form of the drug. The study data obtained were recorded in details and thoroughly analysed.

**Statistical analysis**

The study data were statistically analysed with different percentages.

**RESULTS**

100 patients were treated for exacerbation of non-severe asthma, not needing hospitalisation. All the patients completed the treatment thoroughly. There were no drop-out patients due to adverse effects, none was lost to follow-up and none of the patients withdrew voluntarily. The patients’ adherence to treatment was very high. The demographic characteristics and the baseline PEFR for arformoterol, levosalbutamol, formoterol or salbutamol were comparable. For all the 4 drugs, PEFR showed significant increase compared to the baseline values and there was increase after each dose of the drug. The increases in PEFR after the first, second and the third dose were significantly more with arformoterol than that with levosalbutamol, followed by formoterol and salbutamol (arformoterol > levosalbutamol > formoterol = salbutamol). Adverse effects were negligible in either group. Tolerability was good for both the drugs.

Table 1: Prescription content analysis for different β2 sympathomimetic bronchodilators.

| Prescription contents | Result (%) |
|-----------------------|------------|
| Completeness of prescription contents | 100 (100) |
| Dose of drug | 100 (100) |
| Duration of treatment | 100 (100) |
| Instructions of medication | 100 (100) |
| Frequency of drug intake | 100 (100) |
| Name of the drug | 100 (100) |
| Dosage form of the drug | 100 (100) |

Table 1 depicts the prescription content analysis in percentages for different β2 sympathomimetic bronchodilators. The completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug were observed in 100% of prescriptions.

**DISCUSSION**

In the global public health scenario, asthma still holds an extremely significant position. This study has shown amply comparable results, with no statistically significant difference among the demographic characteristics and the clinical criteria of the patients nebulized with arformoterol, levosalbutamol, formoterol or salbutamol. It was observed that there was an overall increase in the prevalence of the exacerbations of non-severe asthma, among the women, compared to men, with increasing age.

Among the 100 patients with non-severe asthma, the average duration of symptoms was found to be moderately long; there was a visible increase in the pulse rates and respiratory rates; but oxygen saturation was almost within the normal range. The baseline PEFRs were also comparable, among the patients nebulized with arformoterol, levosalbutamol, formoterol or salbutamol. PEFR of the patients showed significant increase compared to the baseline values and there was significant increase after each dose of the drugs given. The increases in PEFR after the first, second and the third doses were significantly more with arformoterol nebulization than with that of levosalbutamol, followed by formoterol and salbutamol. Hence, nebulization with arformoterol was observed to be more efficacious than with that of levosalbutamol, followed by formoterol and salbutamol, as a rescue medication, in exacerbation of non-severe asthma. An analysis of the prescription patterns showed that salbutamol was most commonly prescribed significantly (45 prescriptions, 45%), followed by levosalbutamol (35 prescriptions, 35%), formoterol (15 prescriptions, 15%) and arformoterol (5 prescriptions, 5%) (salbutamol > levosalbutamol > formoterol > arformoterol).
of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug were observed in 100% of prescriptions.

As a starter bronchodilator in acute asthma, short-acting β2 agonists, such as salbutamol, are considered better, for their rapid onset of action. But, these have to be frequently administered, due to their short duration of action, which often causes inconvenience among the patients. Usefulness of long-acting beta-2 agonists such as salmeterol and formoterol as rescue medication in exacerbations of asthma was recently recognized. As a clinically favorable bronchodilator, formoterol have both a rapid onset and long duration of action, with a well-charted safety and tolerability profile. So it can ideally be used as an alternative to short-acting β2 agonists in the management of exacerbations of acute asthma as it causes rapid bronchodilatation, while reducing the need for frequent administration. Being hydrophilic drugs, salbutamol has an ability to reach the β2 receptor from the aqueous phase, thus showing rapid onset of action while, formoterol is much more lipophilic than salbutamol. The aqueous part rapidly activates the β2 receptor, whereas the lipophilic part is taken up into the cell membrane from which it diffuses slowly and thus stimulates β2 receptor over a prolonged period. This action results in rapid onset along with a long duration of action of formoterol, just as demonstrated in the study. Just as salbutamol, onset of action of formoterol is 1-3 min; and after 5-10 min of inhalation, 80-90% of the bronchodilatation occurs; duration of action being 12 hours. The other effects of formoterol on the airway, apart from bronchodilatation, are the inhibition of plasma leakage in the airways through the beta-2 receptor on the endothelial cells of post-capillary venules and sputum α-2 macro-globulin; and the inhibition of mediator release by mast cells, which is an important benefit in the treatment of asthma. Neutrophils are the key inflammatory cells in COPD. Beta-2-adrenergic receptors are expressed on human neutrophils and beta-2-agonists inhibit the release of reactive oxygen species. Some studies have also shown that LABAs (long acting beta agonists) decrease bronchial neutrophils. The efficacy of long-acting beta-2 agonists, such as salmeterol and formoterol, in the maintenance therapy of chronic stable asthma (when used along with an inhaled corticosteroid) and also in acute non-severe asthma, acute severe asthma, exercise induced bronchospasm, childhood asthma and COPD are well-documented. Most studies show the use of formoterol with terbutaline, aerosolizer, or metered dose inhaler. But, there are very less studies showing the use of formoterol in the form of nebulization. Formoterol can be used in patients who are unable or unwilling to use a dry powder inhalation (DPI) or metered dose inhaler (MDI) preparation. Other uses of arformoterol nebulized medication are seen in patients who have repeated episodes of airflow obstruction despite DPI / MDI use and in patients with severe lung function compromise. In some of the short and long term clinical trials, the efficacy of inhaled formoterol has been equal to or greater than that of salbutamol, fenoterol and terbutaline. Recent studies have shown that when inhaled formoterol 12 or 24 μg twice daily was added to the existing inhaled corticosteroid, it improved lung function and reduced asthma symptoms, compared to placebo. Formoterol has got significant therapeutic advantages over shorter-acting beta 2-agonists in the treatment of nocturnal and exercise-induced asthma, as it reduces the need for reliever medication, due to its longer duration of action. When administered 3 and 12 hours before exercise, formoterol conferred more protection than salbutamol. Formoterol is currently recommended for use as an alternative medication to increasing inhaled steroid dosage, in patients whose asthmatic symptoms are inadequately controlled despite therapy, with low to moderate doses of inhaled steroids and intermittent short-acting beta 2-agonists. Oral irritation was found to be a common adverse effect of arformoterol, while with salbutamol - headache, palpitation, oral irritation and tremors were the adverse effects; although there was no statistically significant difference in the adverse effects, among the 4 groups of medications, and these were found to be mild and very few. Hence, arformoterol nebulization was observed to be as safe as levosalbutamol, formoterol or salbutamol nebulization, in the rescue therapy of the exacerbation of non-severe asthma. Evidence of safety of formoterol is also available in the study-literature, even at high doses in patients with asthma and COPD. As there are significantly fewer clinical data available on the use of arformoterol, the safety of this nebulized drug has not been as clearly established as that of racemic formoterol. In a study, dryness of mouth was the commonly reported side effect of formoterol inhalation. Few clinical trials exhibit good tolerability of arformoterol. A study on the use of racemic formoterol and arformoterol in asthma found that both the drugs were well tolerated.

This pharmacoepidemiological study would remain a milestone in the development of newer respiratory, smooth muscular and anti-inflammatory diagnostics and therapeutics; in the development of faster, better, safer, more precise and cost-effective therapeutics; in the cure of patients suffering from asthma; and, finally in the enhancement of respiratory health, healthy life, quality of life, facial beauty and life span, among the generations to come.

CONCLUSION

Arformoterol was more effective, but equally safe, as compared to levosalbutamol, formoterol or salbutamol, in the therapy of the exacerbation of non-severe asthma. Salbutamol was most commonly prescribed significantly, followed by levosalbutamol, formoterol or arformoterol. The completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug were observed in 100% of prescriptions.
ACKNOWLEDGEMENTS

My sincere acknowledgements to the departments of Pharmacology and Respiratory Medicine, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India, and J. J. M. Medical College, Bapuji Hospital and Chigateri General Hospital, Davangere, Karnataka, India, and departments of Clinical Pharmacology and Respiratory Medicine, Hazra Polyclinic and Diagnostic Centre, Hazra Nursing Home, Domjur, Howrah, Kolkata, West Bengal, India, for the successful completion of this research project.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Bousquet J, Mantzouranis E, Cruz AA, Khaled NA, Baena-Cagnani CE, Bleecker ER. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on severe asthma. J Allergy Clin Immunol. 2010;126(5):926-936.
2. Barnes PJ. Pulmonary pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman’s The pharmacological basis of therapeutics. 12th edn. USA: McGraw Hill 2011: 1031-1065.
3. Pollart SM, Compton RM, Elward KS. Management of acute asthma exacerbations. Am Fam Physician. 2011;84(1):40-7.
4. Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr Opin Pulm Med. 2010;16(1):6-12.
5. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
6. Hanania NA, Donohue J, Nelson H, Sciarappa K, Goodwin E, Baumgartner R, et al. Long-term safety and efficacy of nebulized formoterol in subjects with COPD. Chest. 2008;134(4) Suppl 2:106.
7. Kumar H, Goel A, Chand N, Bhushan B, Chander R, Goel A. To Compare the Clinical Efficacy and Safety of Salbutamol and Levosalbutamol Metered-Dose Inhalers in Patients of Bronchial Asthma. Chest. 2010;138(4):160.
8. Pauwels RA, Sears MR, Campbell M, Villasantez C, Huang S, Lindh A, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J. 2003;22:787-94.
9. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32(7):1320-8.
10. Boonsawat W, Charoenratanakul S, Pothirat C, Sawanyawisuth K, Seearmroonguang T, Bengtsson T, et al. Formoterol (oxis) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in Patients with acute severe asthma. Respir Med. 2003;97:1067-74.
11. Bodzenta-Lukaszyn K, Dynek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11:28.
12. Vakily M, Mehar V, Brooks D. Stereoselective Pharmacokinetics and Pharmacodynamics of Anti-Asthma Agents. 2002;36(4):693-701.
13. Cho SH, Oh SY, Bahn JW, Choi JY, Chang YS, Kim YK, et al. Association between bronchodilating response to short-acting β-agonist and nonsynonymous single-nucleotide polymorphisms of β-2-adrenoceptor gene. Clin Exp Allergy. 2005;35(9):1162-7.
14. British Thoracic Society, Scottish Inter Collegiate Guidelines Network. British Guidelines on the Management of Asthma. Thorax. 2008;63(Suppl 4):1-121.
15. Hanania NA, Sethi S, Koltun A, Ward JK, Spanton J, Ng D. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis; 2019;14:117-27.
16. King P. Role of arformoterol in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):385-92.
17. Gopinath VP, Rao MS, eds. Management of acute severe asthma. Medicine Update API. 2010;20:784-5.
18. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention. GINA executive summary. Eur Respir J. 2008;31:143-78.
19. Das SK, Biswas I, Bandyopadhyay AK, Bairagya TD, Bhattacharya S. A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma. Indian J Pharmacol. 2011;43(4):463-5.
20. Arun JJ, Lodha R, Kabra SK. Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial. BMC Pediatr. 2012;12:21.
21. Johnson M. Effects of (β2) agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002;110:282-90.
22. Anderson GP. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective (β2) adrenoceptor agonist bronchodilator. Life Sci. 1993;52:2145-60.
23. Baluk P, McDonald DM. The beta 2 adrenergic receptor agonist formoterol reduces microvascular
leakage by inhibiting endothelial gap form formation.
Am J Physiol. 1994;266:461-8.
24. Greiff L, Wollmer P, Andersson M, Syensson C, Persson CGA. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax. 1998;53:1010-13.
25. Nightingale JA, Rogers DF, Barnes PJ. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med. 1999;159:1786-90.
26. Ketchell RI, Jensen MW, Spina D, O’Connor BJ. Dose-related effects of formoterol on airway responsiveness to adenosine 5’-monophosphate and histamine. Eur Respir J. 2002;19:611-6.
27. Mirza ZN, Kato M, Kimura H. Fenoterol inhibits superoxide anion generation by human polymorphonuclear leukocytes via beta-adrenoceptor-dependent and -independent mechanisms. Ann Allergy Asthma Immunol. 2002;88:494-500.
28. Maneechotesuwan K, Essilfie-Quaye S, Meah S, Kelly C, Kharitonov SA, Adcock IM, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest. 2005;128:1936-42.
29. Jeffery PK, Venge P, Gizycki MJ, Egerod I, Dahl R, Faurschou P. Effects of salmeterol on mucosal inflammation in asthma:a placebo-controlled study. Eur Respir J. 2002;20:1378-85.
30. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2010;(1):CD007694.
31. Bussamra MH, Stelmach R, Rodrigues JC, Cukier A. A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. Ann Allergy Asthma Immunol. 2009;103:248-53.
32. Aalbers R. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years:post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study. Clin Drug Investig. 2010;30(7):439-51.
33. Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev. 2010;(9):CD008418.
34. Baumgartner RA, Mazzetti A, Claus R. Crossover dose-ranging study of arformoterol in patients with COPD. Proc Am Thorac Soc. 2006: 847.
35. Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized formoterol on airway function in COPD:results from two randomized trials. COPD. 2008;5:25-34.
36. Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA, Formoterol for acute asthma in the emergency department:a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2010;104:247-52.

Cite this article as: Hazra M. A pharmacoepidemiological study of prescription patterns of β2 sympathomimetic bronchodilators in exacerbation of non-severe asthma in tertiary care hospitals, not needing hospitalization. Int J Basic Clin Pharmacol 2019;8:2674-2680.